Schizophrenia Research
Volume 66, Issue 1 , Pages 51-57 , 1 January 2004

Obesity as a risk factor for antipsychotic noncompliance

  • Peter J Weiden

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1-718-270-4675; fax: +1-718-270-3355.
    • SUNY Health Sciences Center at Brooklyn, 450 Clarkson Avenue, Box 1203, Brooklyn, NY 11203-2098, USA
    • ,
  • Joan A Mackell

      Affiliations

    • Pfizer, Inc., New York, NY, USA
    • ,
  • Diana D McDonnell

      Affiliations

    • Consumer Health Sciences, Princeton, NJ, USA

Received 20 March 2002 ,Revised 29 October 2002 ,Accepted 4 November 2002.

References 

  1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 1999;156:1686–1696
  2. Babiker IE. Noncompliance in schizophrenia. Psychiatr. Dev. 1986;4:329–337
  3. Becker MH. The health belief model and personal health behaviors. Health Educ. Monogr. 1974;2:324–473
  4. Berken GH, Weinstein DO, Stern WC. Weight gain. A side-effect of tricyclic antidepressants. J. Affect. Disord. 1984;7:133–138
  5. Cookson JC. Side effects during long-term treatment with depot antipsychotic medication. Clin. Neuropharmacol. 1991;14(Suppl. 2):S24–S330
  6. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273–3277
  7. Devlin MJ, Yanovski SZ, Wilson GT. Obesity: what mental health professionals need to know. Am. J. Psychiatry. 2000;157:854–866
  8. Dupuy, H., 1984. The Psychological General Well-Being (PGWB) Index. In: Wenger, N., Mattson, M., Furberg, C., Elinson, J. (Eds.), Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Le Jacq Publishing, Greenwich, CT, pp. 170–183, 353–356.
  9. Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr. Scand., Suppl. 1994;382:11–15
  10. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol. Med. 1992;22:347–352
  11. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med. 1983;13:177–183
  12. Janz NK, Becker MH. The Health Belief Model: a decade later. Health Educ. Q. 1984;11:1–47
  13. Kapur S, Ganguli R, Ulrich R, Raghu U. Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics. Schizophr. Res. 1991;6:49–53
  14. Meyers AW, Klesges RC, Winders SE, Ward KD, Peterson BA, Eck LH. Are weight concerns predictive of smoking cessation? A prospective analysis. J. Consult. Clin. Psychol. 1997;65:448–452
  15. National Institutes of Health . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes. Res. 1998;6(Suppl. 2):51S–209S
  16. Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF. Insulin omission in women with IDDM. Diabetes Care. 1994;17:1178–1185
  17. Revicki DA, Leidy NK, Howland L. Evaluating the psychometric characteristics of the Psychological General Well-Being Index with a new response scale. Qual. Life Res. 1996;5:419–425
  18. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception. 1995;51:283–288
  19. SPSS . SPSS for Windows. Release 9.0.0. Chicago: SPSS; 1998;
  20. Van Putten T, May PR. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch. Gen. Psychiatry. 1978;35:477–480
  21. Van Putten T, May PR, Marder SR. Subjective responses to thiothixene and chlorpromazine. Psychopharmacol. Bull. 1980;16:36–38
  22. Van Putten T, May PR, Marder SR, Wittmann LA. Subjective response to antipsychotic drugs. Arch. Gen. Psychiatry. 1981;38:187–190
  23. Weiden, P.J., Mackell, J., 1999. Differing side effect burden with newer antipsychotics. Presented at: 39th Annual New Clinical Drug Evaluation Unit (NCDEU) Conference, Boca Raton, FL, Poster No. 87.
  24. Weiden PJ, Mott T. Recognition and management of neuroleptic noncompliance in schizophrenia. In:  Shriqui CL,  Nasrallah HA editor. Contemporary Issues in the Treatment of Schizophrenia. Washington, DC: American Psychiatric Press; 1995;p. 411–434
  25. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr. Bull. 1995;21:419–429
  26. Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz Lennon M, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr. Bull. 1994;20:297–310

PII: S0920-9964(02)00498-X

doi: 10.1016/S0920-9964(02)00498-X

Schizophrenia Research
Volume 66, Issue 1 , Pages 51-57 , 1 January 2004

Article Tools